- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02280746
Gluten for Autism Spectrum Disorders
Gluten Dietary Intervention for Autistic Symptoms in Children With Autism Spectrum Disorders - Randomized Open Trial
BACKGRUOUND: Autism spectrum disorder (ASD) is a common condition. The etiology of ASD remains unknown. Recent studies suggest a link between elimination diets and severity of autistic symptoms. The possible effects of a gluten-free diet (GFD) on symptoms remain unknown.
AIM: The aim of the study is to evaluate the impact of gluten challenge on the autistic symptoms in children with autism spectrum disorders (ASD) and on a gluten-free diet (GFD) in comparison to individuals continuing GFD.
METHODS: 70 children with ASD aged 3-5 and 11/12 remaining on GFD for at least 8 weeks will be randomly assigned to gluten-free and gluten-challenge diet.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Autism Spectrum Disorder (ASD) is a neurodevelopmental lifelong disorder, significantly impairing the quality of life of patients and their families. The symptoms are thought to result from interaction between genetics and environment. Treatment is multidisciplinary, based on behavioral therapy, education, and sometimes requires specialized care (i.e. genetics) and pharmacotherapy. The lack of consensus about the etiology of ASD directs researchers to define the condition as combination of symptoms, patient's history data, the impact of co-morbidities (including gastrointestinal disorders), and the effectiveness of various management therapies.
The use of complementary and alternative methods (CAM) of treatment is common and includes especially elimination diets, which are intended to minimize symptoms. The basis for the potentially beneficial impact of dietary intervention has been reported in connection to the correlation between congenital metabolic disorders (phenylketonuria) in patients with ASD and improvements in their overt symptoms in patients with schizophrenia Excessive activity of peptides derived from the metabolism of gluten and casein in individuals with ASD is thought to result in impaired neurotransmission in the brain. The increased permeability of the intestinal barrier, resulting from the inflammatory response (the theory of "leaky gut") in ASD patients, simultaneously promotes excessive absorption of those compounds. Another hypothesis assumes the effectiveness of elimination diets in children with ASD, suggesting allergic background of neuropsychiatric symptoms. Additionally it is emphasized that the lack of ability to communicate symptoms or atypical clinical manifestations (i.e. neuropsychiatric symptoms like hyperactivity, sleep disorders) in children with ASD can make the diagnosis of gastrointestinal symptoms, allergy and other symptoms particularly difficult. Moreover the pain or discomfort may increase the risk of behavioral symptoms.
Review of the literature concerning the effectiveness of gluten-free and casein-free diet (GFCFD) in individuals with ASD reveals a possible bias of the available studies and lack of a definite conclusion. Among 35 identified studies only two randomized controlled trials have been analyzed. The data/information on reported effectiveness of interventions in the behavioral symptoms [mean difference (MD-mean difference) -5.60, 95% CI -9.02 to -2.18, p = 0.001] in Knivsberg's study, is not reliable because of study limitations. Whiteley et al summarized in 2012 the positive effect of GFCFD on various symptoms in ASD patients. However the influence of GFCFD in ASD children can be defined mostly as suggestive because of the methodological limitations. The main biases include: small sample size, unclear process of randomization and allocation, use of different ASD assessment tools, short trial duration, lack of evaluation of patients' compliance to intervention, and other limitations.
The theory of excessive activity of exogenous opioids reports on specific allergies (gluten and casein) suggesting a connection with celiac disease (CD) in subjects with ASD and thus providing a rationale to determine the effect of gluten on gastrointestinal symptoms and consequently on potential behavioral changes in this group of patients.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Anna Piwowarczyk
- Phone Number: +48224523309
- Email: piwowarczyk.ann@gamil.com
Study Locations
-
-
-
Warsaw, Poland
- Recruiting
- Medical University of Warsaw
-
Contact:
- Anna Piwowarczyk
- Phone Number: +48224523309
- Email: piwowarczyk.ann@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Children aged 3-5 and 11/12 years with a diagnosis of ASD
- GFD for at least 8 weeks prior to enrollment
- Minimal scores of 15 on SCQ
- Minimal scores 70 points on Leiter scale
- Consent of caregivers to participate in the study
Exclusion Criteria:
- Gluten-mediated disease (celiac disease, wheat allergy)
- Lack of motivation / opportunity to follow a diet
- Malnutrition (defined according World Health Organization - WHO standards as weight for height <-2 SDS - Standard Deviation Scores)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: A - gluten challenge group
Gluten challenge group - recommended daily intake of at least one normal meal containing gluten such as bread, pita, pasta, biscuits.
|
Intervention will be continued for at least 6 months
|
No Intervention: B - gluten-free diet
Continuation of GFD.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The extent of autistic symptoms based on the Autism Diagnostic Observation Schedule - 2 (ADOS-2)
Time Frame: Change over time - 6 months
|
Change over time - 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The severity of symptoms based on a Social Communication Questionnaire (SCQ)
Time Frame: Change over time - 6 months
|
Change over time - 6 months
|
|
Presentation of gastrointestinal (GI) functional disorders (evaluation based on a parent-report form - Rome III diagnostic questionnaire
Time Frame: Before, after 12 weeks and at the end of intervention
|
Before, after 12 weeks and at the end of intervention
|
|
The extent of adaptive level of functioning on Vineland Adaptive Behavior Scale (VABS)
Time Frame: Change over time - 6 months
|
Change over time - 6 months
|
|
The extent of functioning on Autism Spectrum Rating Scale (ASRS)
Time Frame: Change over time - 6 months
|
Change over time - 6 months
|
|
Anthropometry
Time Frame: Change over time - 6 months
|
Weight, height based on WHO growth charts, comparison of a ratio of weight for height (WfH), and body mass index (BMI)
|
Change over time - 6 months
|
Intelligence test Leiter International Performance Scale
Time Frame: Change over time - 6 months
|
Change over time - 6 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Andrea Horvath, Medical University of Warsaw
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RG 8/2013
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Autism Spectrum Disorders
-
Stanford UniversityCalifornia Department of Developmental ServicesRecruitingAutism Spectrum Disorder | Autistic Disorder | Autism | Autism Spectrum Disorders | Autistic Disorders Spectrum | Autistic Spectrum Disorder | Autistic Spectrum DisordersUnited States
-
Hospital Universitario Dr. Jose E. GonzalezUnknownAutism | Autism SpectrumMexico
-
Emory UniversityNational Institute of Mental Health (NIMH)Terminated
-
University of California, Los AngelesNational Institute of Mental Health (NIMH); Florida State University; Autism...CompletedAutism Spectrum DisordersUnited States
-
University Hospital, MontpellierCaisse Nationale de Solidarité pour l'AutonomieActive, not recruitingAutism Spectrum DisordersFrance
-
Institut National de la Santé Et de la Recherche...Completed
-
Linmarie SikichEunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedAutism Spectrum DisordersUnited States
-
National Human Genome Research Institute (NHGRI)CompletedAutism Spectrum DisordersUnited States
-
University of California, San DiegoCompletedAutism Spectrum DisordersUnited States
-
Stanford UniversityNational Institute of Mental Health (NIMH)Completed
Clinical Trials on Gluten challenge
-
Oslo University HospitalHelse Sor-Ost; Stiftelsen Helse og RehabiliteringRecruiting
-
Hospital Mutua de TerrassaCompletedCeliac Disease | Non-celiac Gluten Sensitivity
-
Joslin Diabetes CenterImmusanT, Inc.CompletedType 1 Diabetes | Celiac DiseaseUnited States
-
AmgenCompletedCeliac DiseaseFinland
-
Oslo University HospitalUniversity of Oslo; South-Eastern Norway Regional Health AuthorityCompleted
-
James Cook University, Queensland, AustraliaNational Health and Medical Research Council, Australia; The Prince Charles... and other collaboratorsCompleted
-
Massachusetts General HospitalTerminated
-
University of Southern DenmarkOdense University Hospital; University Hospital Bispebjerg and Frederiksberg; Hospital of Southern Jutland and other collaboratorsNot yet recruitingInflammatory Bowel Diseases | Ulcerative ColitisDenmark
-
Göteborg UniversitySahlgrenska University Hospital, Sweden; University of Skövde; Ekhaga foundationRecruitingDiabetes | Celiac Disease | Metabolic Disease | AutoimmunitySweden
-
Università degli Studi di BresciaUnknownNon Celiac Gluten SensitivityItaly